pfizer glp 1 drug moves forward with weight-loss GLP-1 pill—a needle-free alternative to Wegovy and Ozempic Pfizer discontinues oral GLP-1 receptor

Discovery of gastric inhibitory polypeptide (GIP) Among those active in the field was John Brown (figure 16), a British-born physiologist, who developed a passion for the gastrointestinal gut while doing a doctorate at the University of Newcastle-upon-Type

Leah Joseph, MD, FACP, offers personalized care to help you understand and choose the right GLP-1 therapy or Ozempic treatment for your health goals

Originally approved for type 2 diabetes management, Ozempic has gained significant attention for its remarkable effectiveness in weight loss

This medication family is known as GLP-1 agonists, and in addition to Ozempic, include Saxenda, Wegovy (which is also semaglutide) and Mounjaro which are already being prescribed off label

The remarkable weight loss and glucose-lowering results achieved by the dual peptides paved the way for triple GIP/GLP-1/glucagon receptor triagonists with the hope that the new combinatorial approaches provide further synergistic metabolic effects